Brad Carver
Co-founder, President, CEO and Chairman @Syndevrx, Inc
Signup · Get unlimited contacts
WORK HISTORY
Co-founder, President, CEO and Chairman @Syndevrx, Inc
SynDevRx, Inc. leads the new approach for cancer drug development called metabo-oncology. This emerging field focuses on the metabolic hormones that drive tumor growth and lead to worse outcomes for cancer patients. Multiple peer reviewed publications estimate the number of cancer patients whose treatment outcomes are effected by their metabolic state is in the in the US alone, and encompasses 13 tumor types. Our drug, evexomostat (SDX-7320) is one of the first novel therapies in development targeting this patient population. We\'re in two phase 2 clinical trials in breast cancer, leading the field of metabo-oncology.\\\\n \\\\n\\\\n \\\\n \\\\n\\\\n \\\\n
EDUCATION
Michigan State University
BA
ABOUT BRAD CARVER
I have over 30 years of experience as a senior biotech executive (co-founder, President…
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.